Redx Pharma Developing treatments for cancer and fibrosis

Redx Pharma: Developing treatments for cancer and fibrosis

11:13 EDT 24 May 2019 | Proactive Investors

Its lead asset, RXC004, is part of a potentially breakthrough group of cancer drugs called Porcupine inhibitors

Original Article: Redx Pharma: Developing treatments for cancer and fibrosis

More From BioPortfolio on "Redx Pharma: Developing treatments for cancer and fibrosis"